MY127797A - 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol-containing pharmaceutical composition with slow release of active indgredient - Google Patents

3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol-containing pharmaceutical composition with slow release of active indgredient

Info

Publication number
MY127797A
MY127797A MYPI20023979A MYPI20023979A MY127797A MY 127797 A MY127797 A MY 127797A MY PI20023979 A MYPI20023979 A MY PI20023979A MY PI20023979 A MYPI20023979 A MY PI20023979A MY 127797 A MY127797 A MY 127797A
Authority
MY
Malaysia
Prior art keywords
ethyl
propyl
methyl
weight
phenol
Prior art date
Application number
MYPI20023979A
Other languages
English (en)
Inventor
Johannes Dr Bartholomaus
Iris Dr Ziegler
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26010444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY127797(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10152469A external-priority patent/DE10152469A1/de
Priority claimed from DE2002148309 external-priority patent/DE10248309A1/de
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of MY127797A publication Critical patent/MY127797A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MYPI20023979A 2001-10-24 2002-10-24 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol-containing pharmaceutical composition with slow release of active indgredient MY127797A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10152469A DE10152469A1 (de) 2001-10-24 2001-10-24 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
DE2002148309 DE10248309A1 (de) 2002-10-16 2002-10-16 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
MY127797A true MY127797A (en) 2006-12-29

Family

ID=26010444

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20023979A MY127797A (en) 2001-10-24 2002-10-24 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol-containing pharmaceutical composition with slow release of active indgredient

Country Status (28)

Country Link
US (7) US20050058706A1 (enExample)
EP (1) EP1439829B1 (enExample)
JP (2) JP4758064B2 (enExample)
KR (1) KR100958045B1 (enExample)
CN (1) CN100402021C (enExample)
AR (1) AR036943A1 (enExample)
AT (1) ATE303802T1 (enExample)
AU (1) AU2002349001C1 (enExample)
BR (1) BRPI0213653B8 (enExample)
CA (1) CA2464578C (enExample)
CO (1) CO5570662A2 (enExample)
CY (1) CY2012022I2 (enExample)
DE (1) DE50204198D1 (enExample)
DK (1) DK1439829T3 (enExample)
EC (1) ECSP045102A (enExample)
ES (1) ES2248622T3 (enExample)
HU (1) HU230161B1 (enExample)
IL (2) IL161587A0 (enExample)
MX (1) MXPA04003742A (enExample)
MY (1) MY127797A (enExample)
NO (2) NO331896B1 (enExample)
NZ (1) NZ532999A (enExample)
PE (1) PE20030527A1 (enExample)
PL (1) PL216535B1 (enExample)
PT (1) PT1439829E (enExample)
SI (1) SI1439829T1 (enExample)
WO (2) WO2003035054A1 (enExample)
ZA (1) ZA200403928B (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
ES2640404T3 (es) 2002-11-22 2017-11-02 Grünenthal GmbH Combinación de analgésicos seleccionados con inhibidores de la COX II
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
PT1842533E (pt) * 2003-08-06 2013-05-17 Gruenenthal Gmbh Forma de dosagem protegida contra abuso
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE602004007905T2 (de) 2004-06-28 2008-05-08 Grünenthal GmbH Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
PL1786403T3 (pl) * 2004-07-01 2013-10-31 Gruenenthal Gmbh Doustna postać dawki zabezpieczona przed nadużywaniem zawierająca (1R, 2R)-3-(3-dimetyloamino-1-etylo0-2-metylo-propylo)fenol
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
PT2012763E (pt) * 2006-04-28 2011-04-29 Gruenenthal Gmbh Combinação farmacêutica que compreende 3-(3-dimetilamino-1-etil-2-metil-propil)fenol e um aine
ATE494889T1 (de) * 2006-04-28 2011-01-15 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
CN101091725A (zh) * 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
DE102007019417A1 (de) 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
EP3170494A3 (en) * 2007-11-23 2017-09-06 Grünenthal GmbH Tapentadol compositions
DK2240431T3 (en) * 2007-12-07 2017-04-10 Gruenenthal Gmbh CRYSTALLIC MODIFICATION OF (1R, 2R) -3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) -PHENOL
CN102014877B (zh) * 2008-01-25 2017-06-06 格吕伦塔尔有限公司 药物剂型
PL2273983T3 (pl) 2008-05-09 2017-01-31 Grünenthal GmbH Sposób wytwarzania pośredniego preparatu proszkowego i końcowej stałej postaci dawkowania z zastosowaniem etapu zestalania rozpyłowego
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
JP6216489B2 (ja) 2008-10-30 2017-10-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 新規の、効力のあるタペンタドール剤形
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
JP2012533585A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化感受性オピオイドのための不正使用防止剤形
WO2011095314A2 (en) * 2010-02-03 2011-08-11 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
WO2011124953A2 (en) * 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
EP2566461A2 (de) * 2010-05-05 2013-03-13 Ratiopharm GmbH Festes tapentadol in nicht-kristalliner form
HRP20151327T1 (hr) * 2010-06-15 2016-01-01 Grünenthal GmbH Farmaceutska kombinacija za lijeäśenje boli
SI2588093T1 (sl) 2010-06-30 2016-10-28 Gruenenthal Gmbh Tapentadol za uporabo pri zdravljenju sindroma razdražljivega črevesja
EP3650439B1 (en) 2010-07-23 2021-02-24 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
NZ608865A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising an anionic polymer
RS54711B1 (sr) 2011-03-04 2016-08-31 Grünenthal GmbH Parenteralno davanje tapentadola
SI3287123T1 (sl) 2011-03-04 2020-07-31 Gruenenthal Gmbh Vodna farmacevtska formulacija tapentadola za peroralno uporabo
EP2694050B1 (en) 2011-04-05 2019-10-02 Grünenthal GmbH Tapentadol for use in treating pain associated with trigeminal neuralgia
WO2012136349A1 (en) 2011-04-05 2012-10-11 Grünenthal GmbH Tapentadol for preventing chronification of pain
EP2701693B1 (en) 2011-04-29 2017-08-23 Grünenthal GmbH Tapentadol for preventing and treating depression and anxiety
NO2680834T3 (enExample) 2011-05-03 2018-03-17
MX348491B (es) 2011-07-29 2017-06-15 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco.
PT2736497T (pt) 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente a adulteração proporcionando libertação imediata de fármaco
RS56947B1 (sr) * 2011-07-29 2018-05-31 Gruenenthal Gmbh Intratekalno ili epiduralno davanje 3-[(1s,2s)-3-(dimetilamino)-1-etil-2-metilpropil]fenola
EP2606879A1 (en) 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
ES2692944T3 (es) 2012-04-18 2018-12-05 Grünenthal GmbH Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP3003283A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP2942054A1 (en) 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
AU2016239772B2 (en) 2015-03-27 2021-05-13 Grünenthal GmbH Stable formulation for parenteral administration of Tapentadol
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP3231420A1 (en) 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
JP7160799B2 (ja) 2016-09-23 2022-10-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口投与用安定製剤
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic
ES2963929T3 (es) * 2017-05-29 2024-04-03 Gruenenthal Gmbh Forma farmacéutica oral multipartículas que proporciona liberación prolongada de tapentadol
EP3875079A1 (en) 2020-03-02 2021-09-08 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
AU2020100441B4 (en) * 2020-03-02 2020-06-18 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
BR112022017700A2 (pt) 2020-03-02 2023-01-17 Gruenenthal Gmbh Forma de dosagem fornecendo liberação prolongada de sal de ácido fosfórico de tapentadol
PL3875077T3 (pl) * 2020-03-02 2024-03-11 Grünenthal GmbH Postać dawkowania zapewniająca przedłużone uwalnianie soli kwasu fosforowego tapentadolu
AU2020100442B4 (en) * 2020-03-02 2020-06-18 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
MX2022011505A (es) * 2020-03-16 2022-10-07 Gruenenthal Gmbh Comprimido ranurado.
DE202020104285U1 (de) 2020-07-24 2020-12-18 Grünenthal GmbH Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure
DE202020005470U1 (de) 2020-11-10 2022-01-25 Grünenthal GmbH Darreichungsformen mit verlängerter Freisetzung eines Salzes von Tapentadol mit L-(+)-Weinsäure
PE20240113A1 (es) 2020-11-10 2024-01-22 Gruenenthal Chemie Formas de dosificacion de liberacion sostenida de una sal de tapentadol con acido l-(+)-tartarico
PT3995135T (pt) * 2020-11-10 2022-09-08 Gruenenthal Gmbh Forma de dosagem que proporciona libertação prolongada de um sal de tapentadol com ácido l-(+)-tartárico

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
DE2117239A1 (de) 1971-04-08 1972-11-16 König, Wilhelm, 4712 Werne Verfahren zum Erstellen von Wänden aus Schalungssteinen
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5567587A (en) 1983-01-10 1996-10-22 Gen-Probe Incorporated Method for detecting, the presence and amount of prokaryotic organisms using specific rRNA subsequences as probes
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
GB8519310D0 (en) 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
EP0661045B1 (en) * 1992-09-18 2002-07-03 Yamanouchi Pharmaceutical Co. Ltd. Sustained-release hydrogel preparation
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
DE69433055T2 (de) 1993-11-17 2004-02-26 Lequio Pharma Co.Ltd., Naha Zusammensetzung zum heilen von verletztem gewebe, verfahren für ihre herstellung und ihre verwendung
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
CN1125572A (zh) * 1994-12-28 1996-07-03 顺德市广容制药厂 一种罗通定痛释片的制作方法
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
DE19525137C2 (de) 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
DE19609847A1 (de) 1996-03-13 1997-09-18 Gruenenthal Gmbh Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
WO1998001117A1 (en) * 1996-07-08 1998-01-15 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
CA2290624C (en) * 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
DE19901683B4 (de) 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
CN1407884B (zh) * 1999-10-29 2012-06-20 欧罗赛铁克股份有限公司 控释氢可酮制剂
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
DE10248309A1 (de) 2002-10-16 2004-04-29 Grünenthal GmbH 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung

Also Published As

Publication number Publication date
BR0213653A (pt) 2004-10-26
CY2012022I1 (el) 2015-08-05
JP4758064B2 (ja) 2011-08-24
CN100402021C (zh) 2008-07-16
MXPA04003742A (es) 2004-07-23
AR036943A1 (es) 2004-10-13
US20050058706A1 (en) 2005-03-17
JP2005506367A (ja) 2005-03-03
US20170087103A1 (en) 2017-03-30
NZ532999A (en) 2007-06-29
WO2003035054A1 (de) 2003-05-01
NO2012007I2 (no) 2013-01-02
US20160151309A1 (en) 2016-06-02
CA2464578C (en) 2011-10-11
ZA200403928B (en) 2005-07-27
HUP0402104A2 (hu) 2005-03-29
ES2248622T3 (es) 2006-03-16
DE50204198D1 (de) 2005-10-13
PL216535B1 (pl) 2014-04-30
BRPI0213653B8 (pt) 2021-05-25
CA2464578A1 (en) 2003-05-01
PT1439829E (pt) 2005-11-30
US20130237608A1 (en) 2013-09-12
US20120034304A1 (en) 2012-02-09
KR100958045B1 (ko) 2010-05-17
EP1439829A1 (de) 2004-07-28
ECSP045102A (es) 2004-06-28
CO5570662A2 (es) 2005-10-31
EP1439829B1 (de) 2005-09-07
US20180221308A1 (en) 2018-08-09
KR20040047964A (ko) 2004-06-05
PL369756A1 (en) 2005-05-02
HU230161B1 (en) 2015-09-28
CN1607947A (zh) 2005-04-20
NO331896B1 (no) 2012-04-30
AU2002349001C1 (en) 2022-04-14
NO20041924L (no) 2004-05-11
BRPI0213653B1 (pt) 2018-04-03
DK1439829T3 (da) 2005-10-10
SI1439829T1 (sl) 2006-02-28
AU2002349001B2 (en) 2003-05-06
JP2010280697A (ja) 2010-12-16
NO2012007I1 (no) 2012-05-21
IL161587A0 (en) 2004-09-27
PE20030527A1 (es) 2003-07-26
ATE303802T1 (de) 2005-09-15
HK1068539A1 (en) 2005-04-29
US11007156B2 (en) 2021-05-18
CY2012022I2 (el) 2015-08-05
US20200038344A1 (en) 2020-02-06
IL161587A (en) 2009-12-24
WO2003035053A1 (de) 2003-05-01

Similar Documents

Publication Publication Date Title
MY127797A (en) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol-containing pharmaceutical composition with slow release of active indgredient
CA2476201A1 (en) Modified release formulations of at least one form of tramadol
WO1997012583A3 (en) Stable compositions containing n-propargyl-1-aminoindan
EP1287822A3 (en) Mesalazine controlled release oral pharmaceutical compositions
WO2001047498A3 (en) Hydrogel-driven layered drug dosage form comprising sertraline
CA2361716A1 (en) Method of preparing alkylated salicylamides
DE60124294D1 (de) Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe
IL111647A (en) Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
WO2001078725A3 (en) Modified release formulations containing a hypnotic agent
BR0212475A (pt) Composições farmacêuticas
BR0007360A (pt) Composição de liberação controlada
PT1401501E (pt) Composicoes farmaceuticas orais com libertacao modificada do ingrediente activo
BR9916361A (pt) Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
MY139606A (en) Sustained-release composition and process for producing the same
WO2005009329A3 (de) 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung
EA200400628A1 (ru) Таблетки метформина с контролируемым высвобождением активного компонента
MXPA04003506A (es) Metodo para la preparacion de una composicion farmaceutica que comprende acido 5-aminosalicilico para el uso en el tratamiento de la colitis ulcerativa y de la enfermedad de crohn.
WO2004078111A3 (en) Extended release minocycline compositions and processes for their preparation
MY137570A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease
CA2397942A1 (en) Controlled release pharmaceutical composition containing tramadol hydrochloride and method for its preparation
WO2006107593A3 (en) Matrix-based pulse release pharmaceutical formulation
DK1121109T3 (da) Tofaset sammensætning med tramadol
WO2005107702A3 (en) Sustained release, mucoadhesive vaginal pharmaceutical compositions
WO2007031326A3 (de) Retardformulierung von 3-(2-dimethylaminomethyl-cyclohexyl)-phenol